drugset
drugset / Trial / NCT05350800

A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy Participants

NCT05350800 ↗

Phase 1 Completed 68 enrolled Bristol-Myers Squibb
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, drug levels of BMS-986369 following administration of single ascending oral doses (SAD) in healthy adult participants. The study will also explore the effect of high-fat meal on the single-dose drug level of BMS-986369 in healthy adult participants.

Timeline

Start
2022-09-12
Primary completion
2023-05-04
Completion
2023-05-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Golcadomide Other / unclassified — Oral

Indications

No indication recorded.